cyrilzakka/clinical-trials huggingface dataset:
Intralesional Bleomycin Versus Cryotherapy for Treatment of Cutaneous Warts

The purpose of the study was to determine the efficacy of intralesional bleomycin in comparison to cryotherapy on participants having cutaneous warts.

This study was conducted in the Department of Dermatology of Jinnah Postgraduate Medical Centre, Karachi from January to June 2021 after receiving approval from the institutional ethical and research committee of hospital.

Sample size was calculated through NCSS software. Total of one fifty four non-admitted patients were assigned two study groups with equal sample size of 77 randomly through lottery method. Those patients aged between 18 to 60 years of either gender with cutaneous warts for \> 1 week to 48 weeks were included after written informed consent. Patients treated previously for warts by any methodology, with history of vascular disease, immunocompromised, hypertension, cardiovascular disorder, pregnancy, lactation and hypersensitivity to lidocaine were excluded.

All demography, clinical history was recorded by a principal investigator on a predesigned Performa , informed written consent was taken before enrolment.

Group A received intralesional bleomycin 0.1% therapy until the lesion blanched. It was prepared manually by diluting 15 mg powder in 5 ml distilled water and then each ml was further diluted by adding 2ml of 2% lignocaine, double the amount taken from the vial, so that concentration became 1mg/1ml (0.1%). Group B patients were treated with liquid nitrogen with the help of a cotton swab wrapped on a wooden stick and was applied firmly with 01 mm extra healthy skin margin until the lesion blanched.

Follow-up was carried out at 02, 04 and 06 weeks. Both the groups were assessed and compared for efficacy after 6 weeks of therapy. SPSS 23 was used for analyzing data.

Eligibility Criteria:
Inclusion Criteria:

* • Age18 to 60 years

  * Either gender.
  * Diagnosed cases of cutaneous warts as per operational definition for \> 1 week to 48 weeks.

Exclusion Criteria:

* • Previously treated for warts by any methodology, assessed by history and clinically.

  * Patients with hypertension, cardiovascular disorder, pregnancy, lactation, vascular diseases, assessed by history, clinically \& by positive autoimmune profile.
  * Hypersensitivity to lidocaine.
  * No given informed written consent.
A Clinical Observation on Electrophysiology in Headache Patients With Myofascial Trigger Points

Through an observational, cross-sectional study, muscle activity was compared among 21 subjects with episodic headache, 17 subjects with chronic headache and 17 age-matched healthy controls. Muscle activity was bilaterally tested with needle electromyography at rest status, targeting at myofascial trigger points (MTrPs) in the frontal, temporal, sternocleidomastoid (SCM), splenius capitis, splenius cervicis and trapezius of each subject. Headache characteristics (intensity, frequency and duration), McGill Pain Questionnaire (MPQ) and Digital Span (DS) scales were secondary outcomes. The correlation between muscle activity and headache characteristics was also analyzed.

This study provides preliminary evidence of the relationship between muscle and the chronicity of headache.


Eligibility Criteria:
Inclusion Criteria:

1. Have at least one onset of headache in the last week,
2. Aged between 18-65 years,
3. No special treatment or invasive test on pericranial muscles in the last month, and no painkillers or muscle relaxants in the last week.

Exclusion Criteria:

1. History of surgery, trauma, tumor and spinal disease affecting the head and neck,
2. Being unable to cooperate with inspection and questionnaires for any reason (severe systemic disease, bleeder, communication barriers and so on),
3. People with definite mental disorders such as anxiety and depression.
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change

This study will test whether reduced-dose radiotherapy is an effective treatment for metastatic tumors with an ATM mutation. The researchers want to find the lowest dose of radiation that would still be effective to treat these tumors.


Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed malignancy with at least one metastatic lesion referred for palliative radiotherapy
* Pathogenic mutation in ATM (somatic and germline allowed)
* ECOG performance status 0-2
* Age ≥ 18 years.
* Able to provide informed consent.
* Patients at reproductive potential must agree to practice an effective contraceptive method during radiation treatments.
* Expected life expectancy of at least 6 months

Exclusion Criteria:

* Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances.
* Serious medical co-morbidities precluding radiotherapy.
* Pregnant or breast-feeding women.
* Lesions excluded from de-escalation include regions in which the risk of local disease progression is unacceptably high, including CNS disease and cord compression, and areas in which re-irradiation would not be feasible, including spinal cord overlap.
Optimizing the Assessment of Refractive Outcomes After Cataract Surgery

The purpose of this study is to evaluate current available assessments (automated vs. manual) with which manifest refraction data and biometric variables are obtained to understand if data from an automated refractor can be utilized to optimize the A-constant as well as manual subjective refraction (ie, to a clinically insignificant difference). The A-constant is the calculated number that helps the surgeon determine which IOL should be implanted in the eye during cataract surgery.

Subjects will be implanted with ACRYSOF® IQ Monofocal IOL Model SN60WF. Standard clinical practice will be followed for pre-operative testing, IOL power estimation and IOL implantation. Only one eye will be enrolled in the study per surgeon determination. The eye will undergo both an automated and manual manifest refraction assessment at 3 months postoperative.

Eligibility Criteria:
Inclusion Criteria:

* Able to understand and sign an Ethics Committee/Institutional Review Board approved Informed Consent;
* Willing and able to attend all scheduled study visits as required per protocol;
* Diagnosed with cataract in one or both eyes;
* Planned cataract removal by phacoemulsification with implantation of a monofocal IOL; laser refractive procedures for incisions (primary and sideport), capsulorhexis and lens fragmentation are allowed;
* Preoperative keratometric astigmatism ≤ 1.0 diopter (D);
* Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

* Women of childbearing potential, pregnant, or breast-feeding;
* History of ocular pathology, ocular inflammation, or ocular conditions, as specified in the protocol;
* Previous intraocular or corneal surgery;
* Use of systemic medications that, in the opinion of the Investigator, may confound the outcome or increase the risk of complications to the subject;
* Any medical condition that, in the opinion of the Investigator, may confound the results of this study, prohibit the completion of the study assessments, or increase the risk for the subject;
* Other protocol-defined exclusion criteria may apply.
Overnight Post-Exercise Recovery After Protein Ingestion Prior to Sleep

The purpose of this study is to examine the effects of post-exercise protein ingestion prior to sleep on overnight protein kinetics and muscle recovery.


Eligibility Criteria:
Inclusion Criteria:

* Male
* Age between 20 and 30 years
* Healthy, recreationally active
* BMI \<25 kg/m2

Exclusion Criteria:

* Use of medication
Onco-haematology Vigilance Card

The objective of this study is to show the interest of setting up a drug vigilance card in Oncology in order to reinforce patient safety, develop compliance and avoid drug interactions when the patient consults town professionals or other specialists.

Recent developments in oral chemotherapy and targeted therapies have radically changed cancer patient management; ambulatory care is now common. Oral therapies afford many advantages, improving patient quality of life and autonomy by reducing hospital stays and involving patients in their own care. Optimising the care of cancer patients at home requires the coordinated intervention of hospital and town healthcare professionals and involvement of the patient to detect, prevent, and manage adverse events, avoid drug interactions, and educate patients. Preliminary work in haematology has highlighted (n = 31 patients) the interest of a "drug vigilance card" in three indications (Chronic Lymphocytic Leukaemia, Chronic Myeloid Leukaemia and Multiple Myeloma) with an increase in the town-hospital link.

This is an prospective cohort study. Following the announcement consultation, in addition to the personalised care plan, the information about the treatment will be contained in a drug monitoring card that will be given to the patient by the health professional (doctor or nurse). This drug monitoring card should be presented to the health professionals by the patient. During the entire period of treatment, the patient will have a card.

Eligibility Criteria:
Inclusion Criteria:

* All patients treated at Limoges University Hospital in Medical Oncology department, receiving oral treatment (chemotherapy and/or targeted therapies)

Exclusion Criteria:

* All patients treated at Limoges University Hospital in Medical Oncology department, receiving hormone therapy or IV treatment only.
Breast Cancer Active Surveillance, Alternative Option, Aspirin Included

Experimental, clinical, and epidemiological studies have all demonstrated the strong association between chronic inflammation and cancer, and many studies have correlated the prolonged presence of the inflammatory milieu with an increased risk for developing cancer.(1) Although the potential mechanism for aspirin preventing breast cancer is not known, possible pathways may involve platelets, inflammation, cyclooxygenase (COX) 2, hormones, or PI3 kinase. (2).

In actual clinical practice there exist clear guidelines for the use of aspirin in colorectal cancer but no such guidelines exist for the use of aspirin in breast cancer patients.

In the Unit´s proper experience, in patients under active surveillance and metastatic ones some present very good responses both in the neoadjuvant and in the metastatic setting but investigators intend to provide evidence and not just the experience. This study patients are proposed to combine their standard treatment with aspirin.

Breast cancer patients with diagnosis of Ductal or Lobular Invasive Carcinoma or CDis that refuse to underwent surgery or are not qualified for, and independently of age or of their actual staging, are going to be allocated, randomly and in double masked way to one of two arms:

Arm 1: standard Unit´s protocol + placebo Arm 2: standard Unit´s protocol + aspirin

Eligibility Criteria:
Inclusion Criteria:

Every adult (above 18) y.o.patient with histologic diagnosis of Breast Cancer that refuse or is not suitable for surgical treatment, or with metastatic disease, remaining this way in an "active surveillance"

Exclusion Criteria:

Allergy or toxicity to aspirin
Minimally Invasive Surgery for Ponto Bone Anchored Hearing Implants

The objective of this study is to make a comparison between two surgical techniques used when implanting a Ponto bone anchored hearing system.


Eligibility Criteria:
Inclusion Criteria:

* Adult patient, i.e. ≥ 18 years of age
* Eligible for the Ponto system

Exclusion Criteria:

* Known history of immunosuppressive disease
* Use of systemic immunosuppressive medication
* Receiving bilateral bone anchored hearing system
* Relevant dermatological diseases as judged by the investigator
* Not being able to finish the study, for example because of failure to complete the questionnaires
* Participating in another study with medical aids or medication
* When there is no suitable implantation-site for the 4 mm implant during surgery because of insufficient bone quality.
The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients

The purpose of this study is to determine whether Certolizumab pegol can rapidly reduce the inflammatory changes and inhibit erosions on hand and wrist MRI in patients with active moderate to severe rheumatoid arthritis.

The primary objective of this study is to evaluate the efficacy of CSP used in combination with MTX in patients with active moderate to severe RA by evaluating change from baseline in synovitis and bone edema MRI scores at week 6.

Eligibility Criteria:
Inclusion Criteria:

* moderate to severe RA (DAS \> 4.4)
* at least two swollen and tender joints in one of the hand/ wrist
* patients must have failed at least one non-biologic or biologic DMARDs
* currently receiving MTX therapy

Exclusion Criteria:

* concomitant diseases or pathological conditions that could interfere and impact the assessment of the study treatment
Prospective Randomized Trial Comparing Urinary Diversion After Robot-assisted Radical Prostatectomy

The purpose of the study is to determine, whether the urinary diversion via suprapubic cystostomy compared to transurethral catheterization after robot-assisted radical prostatectomy superior the postoperative patient comfort and reduce the postoperative bacteriuria.


Eligibility Criteria:
Inclusion Criteria:

1. Minimum age of 18 Years
2. Voluntarily agreement to participate in this study
3. Written informed-consent
4. Release of medical records for regulatory or research purposes
5. Clinically organ-confined prostate cancer

Exclusion Criteria:

1. BMI \>40
2. History of catheterization
3. History of radiation
4. History of chemotherapy
5. Person's participating in any other research
6. Unable to provide informed consent
Estetrol for the Treatment of Female Sexual Arousal Disorder in Postmenopausal Women

The goal of this clinical trial is investigating estetrol (E4) in women after menopause, suffering from sexual arousal disorder. The main question it aims to answer is: is 20 mg estetrol monohydrate effective in the treatment of sexual arousal disorder in women after their menopause. Participants will visit the clinic 7 times and complete a daily diary while receiving estetrol or placebo for 12 weeks. Placebo is a pill that looks the same as estetrol but has no active ingredient. Researchers will compare estetrol and placebo to see if estetrol has an effect on the sexual arousal of the participants.


Eligibility Criteria:
Main Inclusion Criteria:

- Hysterectomized postmenopausal women, ≥40 up to ≤65 years, diagnosed with Female Sexual Arousal Disorder

Main Exclusion Criteria:

* Not willing to stop any hormonal products during their participation in the study
* History of unresolved sexual trauma or abuse that is contributing to any sexual dysfunction problem
* Have experienced a recent major life stress or relationship discord that could interfere with sexual activity
* Clinically significant abnormal gynecological findings
* History of malignancy, with the exception of basal cell or squamous cell carcinoma of the skin
* Systolic BP higher than 140 mmHg, diastolic BP higher than 90 mmHg
* Is judged by the investigator to be unsuitable for any reason
Efficacy and Safety of Regan Tangjiang for Treating the Common Cold With Wind-heat Syndrome

Efficacy and Safety of Regan Tangjiang for treating the common cold with wind-heat syndrome: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo and Active-Controlled Phase 2b Study


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of common cold according to Western Medicine，with symptoms onset and fever less than 24 hours prior to randomization；
* After the onset of the disease, with the following symptoms: sore throat and axillary temperature between 38.5 and 38.9°C inclusive.
* Diagnosis of wind-heat syndrome according to TCM；
* Aged between 18 to 65 years；
* Willingness to participate and to sign the informed consent form.

Exclusion Criteria:

* Participants with Pneumonia, suppurative tonsillitis, acute tracheobronchitis, acute and chronic sinusitis, pulmonary tuberculosis and other diseases;
* White blood cell count \>11.0×109/L, or neutrophil percentage\>75%;
* Participants with liver function 1.5 times higher than the normal upper limit or serum creatinine higher than the normal upper limit;
* Participants with severe primary diseases of cardiovascular, brain, lung, liver, kidney and hematopoietic system , such as viral hepatitis, hemophilia, diabetes, psychosis and so on;
* Participants who had used other drugs to treat common cold after the onset of the disease, including antivirals, antibiotics and traditional Chinese medicine.
* Women who are pregnant or breast-feeding;
* Allergic condition (refer to history of allergy to two or more drugs or food) or allergy to the drug composition(s);
* Participation in another clinical study of an investigational drug within 3 months
* Participants who are not suitable for the trial decided by the researchers for any reason, such as pregnancy, frequently changes in work or living environments.
Bone Intake Proteins and Muscle Mass Deficiency in Proximal Femur Fractures

The aim of this clinical trial is to compare serum concentration of bone intake proteins \[ sex hormone-binding globulin (SHBG), cross linked C-telopeptide of type I collagen (CTX-I)\] and muscle atrophy marker \[creatine kinase (CK-MB)\] between patients after the fracture of proximal femur and their age corresponding counterpart without the fracture. The main question it aims to answer is:

• Is the higher concentration of bone intake proteins and muscle atrophy marker a predictive factor of proximal femur fracture?

The part of participants (Group 1) will be hospitalized at the Department of Orthopaedics and Rehabilitation and will undergo a surgical treatment (open reduction of the fracture). The rest (Group 2) will be admitted to the Department of Internal Medicine. Participants of both Groups will have the blood sample test taken, to evaluate and compare the serum concentration of SHBG, CTX-I and CK-MB proteins.


Eligibility Criteria:
Inclusion Criteria:

* Age over 65
* Proximal femur fracture (Group 1)

Exclusion Criteria:

* neoplasmatic history in the anamnesis,
* prevalent fracture
* mental illness
* immune disease affecting protein balance
Effect of Cranberry Extract on the Urinary System

In this study, we will try to emphasize the effects of using cranberry tablets, which is an alternative to antibiotic therapy, during uncomplicated urinary tract infections (only urinary tract, bladder and kidney infections did not).

This study was Istanbul Kartal Dr. Lütfi Kırdar Training and Research Hospital Emergency Medicine Clinic and Kırklareli Training and Research Hospital Emergency Service and Internal Medicine Polyclinic. Our study; includes patients who applied to the Emergency Department and Internal Medicine outpatient clinic with the complaint of dysuria and had normal WBC, CRP, urea, and creatinine values in their analysis, and leukocyturia was found in the urine test. Two options were offered in the treatment to these patients. Vaccinium Macrocarpon Aiton preparation or fosfomycin was given for seven days. The patients were asked whether their complaints had decreased according to the Lykert-Type verbal scale at the time of admission and on the first, third, and seventh days. When the treatment was finished, leukocytes were checked in the urinalysis. This outcome was compared between the 2 treatment options. We also noted whether nausea.

Eligibility Criteria:
Inclusion Criteria:

* Older than 18
* who have urinary tract inflammation
* who haven't kidney dissease previous

Exclusion Criteria:

* Younger than 18
* Who have kidney inflammation
* Pregnant patients
* Who have blood test abnormal (WBC, Ure, Creatin, CRP high level)
Identification of Risk Factors Parkinson's Disease by Convergence Strategy

Using this convergence approach from a limited group of subjects with non-diseased controls, patients with Parkinson's disease or related diseases, we will be able to limit the number of potential genes of specific susceptibility to Parkinson disease. These genes will then be studied using a case-control genetic epidemiology approach. The risk of developing the disease will then be evaluated according to clinical, biological and environmental variables collected in Parkinson's subjects and healthy controls in the second group of subjects. The specificity of the genetic associations found will be evaluated in subjects with Parkinson's disease.


Eligibility Criteria:
Inclusion Criteria:

* Inclusion criteria for Parkinson's patients and "related diseases" controls:
* Parkinsonian patients meeting the Gelb criteria
* Patients with other neurodegenerative disease (such as other Parkinson syndrome or synucleopathies) meeting the criteria set out in Appendix 2 (Lewy Bodies dementia, Parkinson's disease with dementia, MultiSystem atrophy, Progressive Supranuclear Paralysis) , Amyotrophic Lateral Sclerosis, Restless Legs Syndrome, Alzheimer's Disease).
* Woman of childbearing age having an effective means of contraception.
* Informed consent signed by the subject or his legal representative.
* For demented subjects coming for consultation or day hospitalization with an accompanying person, signature of the legal representative.

Criteria for inclusion of non-ill controls:

* Absence of rest trembling, bradykinesia and stiffness
* MMSE (Mini Mental State Examination) greater than 25
* Woman of childbearing age having an effective means of contraception.
* subject having signed the informed consent.
* No family history of neurodegenerative disease that started before age 70. These controls will not present any Parkinsonian signs during the clinical evaluation. They may have functional disabilities whose cause is known and unrelated to a neurodegenerative disease with a cognitive function measurement greater than 25 in the MMSE test.

Exclusion Criteria:

* Criteria for non-inclusion of patients:
* Clinical criteria for exclusion of the diseases described
* Participation in another therapeutic trial or in the exclusion period of a previous clinical trial.

Criteria for non-inclusion of non-ill controls:

* Functional discomfort in daily life of unknown cause
* MMSE less than 25
* Participation in another therapeutic trial or in the exclusion period of a previous clinical trial.